Yissum - Research Development Company of the Hebrew University

iCOUGH: Accumulative Breath Cougher for Spinal Cord Injuries

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

The device incorporates an active drug delivery PEP valve device that provides active, accumulative dosing of large volume of aerosolized drug or air. This technology enables the distribution of the substance to the lower respiratory system. also incorporated is a Venturi-based insufflation-exhalation system that simulates cough by predefined parameters activated independently or by stimuli from the patient

Project ID : 40-2018-4614

Description of the technology

Keywords

Medical Devices, Drug Delivery, Respiratory System

Current development stage

Proof-of- Concept and a demonstration designed.

A prototype suitable for mass production may be produced within 12 months.

Application

Spinal cord injuries (SCI) impair the ability to breathe deeply and cough forcefully. As a result, SCI patients cannot clearthemucusproduced in the airway system, which can lead to morbidity and mortality associated with respiratory infections and decreased quality of life.

Current solutions

Current solutions vary and include one of the possible techniques:

  • The utilization of professional physiotherapists who perform physical maneuvers that assists patients to cough.
  • Various expensive hospital coughers that are immobile and not adjusted for home usage and require the expertise and assistance of medical personnel.
  • Various mechanical inflation-exhalation devices that are fitted for home use, but currently can only be used with others' assistance.

Our Innovation

We deliver an efficient, convenient, cost-effective and accessible way to produce cough among SCI patient that can be operated solely by the patient.

The device incorporates an active drug delivery PEP valve device that provides active, accumulative dosing of large volume of aerosolized drug or air. This technology enables the distribution of the substance to the lower respiratory system.

In addition, we incorporate a venturi-based insufflation-exhalation system that simulates cough by predefined parameters activated independently or by stimuli from the patient.

Advantages

Unlike standard nebulizers and inhalers, our device actively delivers air or drug using large volume of pressurized air directly to the target site. As a result, it does not rely on distribution, the user’s breath or diffusion. Therefore, thr distribution either could go all the way to the alveoli itself, or directly to obstructed or blocked region.

Opportunity

SCI patients suffer from 38,000 complications per year due to impaired coughing. The average cost per patient reaches up to $66K.

Project manager

Aviv Shoher
SVP BUSINESS DEVELOPMENT

Project researchers

Yaakov Nahmias
HUJI, School of Computer Science and Engineering
Bio-Engineering

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Medical Health related
  • medical device
  • Life Science & Biotechnology
  • medical devices

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.